文献速递痛风与晶体性关节病

急性痛风发作期启用非布司他不延长当前发作:一项随机临床试验

Initiation of febuxostat for acute gout flare does not prolong the current episode: a randomized clinical trial.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该随机、安慰剂对照、单盲、多中心试验纳入140例72小时内急性痛风发作患者,比较发作期启用非布司他40 mg/日与安慰剂对发作持续时间的影响。结果显示两组缓解天数无显著差异(5.98天 vs 6.50天,P=0.578),7天内缓解率亦无差异(84.38% vs 76.92%,P=0.284)。结论为急性发作期启用非布司他不延长发作持续时间。

要点

  • 急性痛风发作期启用非布司他40 mg/日不延长当前发作持续时间。
  • 两组第7天关节疼痛、肿胀、压痛及红斑评分无统计学显著差异。
  • 非布司他组第7天平均血尿酸显著低于安慰剂组(362.62 vs 507.54 μmol/l,P=0.000)。

核心结论

  • 急性痛风发作期启用非布司他40 mg/日不延长急性发作持续时间。

研究设计与样本

  • 随机、安慰剂对照、单盲、多中心试验,纳入72小时内急性痛风发作患者140例,按1:1随机分为安慰剂组和 non布司他40 mg/日组各70例。
  • 所有患者前7天服用双氯芬酸150 mg/日,第8天起开放标签,非布司他40 mg/日与双氯芬酸75 mg/日维持至第28天。

主要发现

  • 平均缓解天数安慰剂组5.98天(中位7.00,IQR 2.45天),非布司他组6.50天(中位7.00,IQR 3.67天),P=0.578。
  • 7天内缓解率安慰剂组84.38%,非布司他组76.92%,P=0.284。
  • 第1、3、5、7天关节疼痛、肿胀、压痛及红斑评分两组无统计学显著差异。
  • 第7天平均血尿酸安慰剂组507.54 μmol/l,非布司他组362.62 μmol/l,P=0.000。
  • 第8至28天复发痛风发作率安慰剂组10.00%,非布司他组6.56%,P=0.492。

关键数值与推荐

  • 主要结局为缓解天数,非布司他组与安慰剂组分别为6.50天和5.98天(P=0.578)。
  • 7天内缓解率非布司他组76.92%,安慰剂组84.38%(P=0.284)。
  • 第7天平均血尿酸非布司他组362.62 μmol/l,安慰剂组507.54 μmol/l(P=0.000)。
  • 第8至28天复发率非布司他组6.56%,安慰剂组10.00%(P=0.492)。

临床怎么用

  • 急性痛风发作期可启用非布司他40 mg/日,不延长当前发作持续时间。
  • 发作期启用非布司他需联合双氯芬酸150 mg/日控制炎症,第8天起双氯芬酸减至75 mg/日。

局限性

  • 单盲设计可能引入实施偏倚。
  • 样本量140例,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Our objective was to determine whether initiation of febuxostat during an acute gout flare prolongs the current episode. METHODS: In this randomized, placebo-controlled, single-blinded, multicentre trial, patients with acute gout flares within 72 h were randomized (1:1) to the placebo and febuxostat (40 mg/day) groups. All patients were administered diclofenac (150 mg/day) for 7 days and then open-labelled on the eighth day. Febuxostat 40 mg daily and diclofenac 75 mg daily were administered from day 8 through 28 for the remission period. The dose of diclofenac was 150 mg/day before remission in both arms, and the original protocol was maintained until remission. The primary outcome was 'days to resolution'. RESULTS: We randomized 140 patients, 70 into each arm. The mean days to resolution was 5.98 days [median 7.00, interquartile range (IQR) 2.45 days] for the placebo and 6.50 days (median 7.00, IQR 3.67 days) for the febuxostat group (P = 0.578). The rate of resolution within 7 days was 84.38% for the placebo group and 76.92% for the febuxostat group (P = 0.284). There were no statistically significant differences in joint pain, swelling, tenderness and erythema scores at days 1, 3, 5 and 7. The mean serum uric acid levels were 507.54 and 362.62 μmol/l for the placebo and febuxostat group, respectively, on day 7 (P = 0.000). The rate of recurrent gout flares was 10.00% for the placebo group and 6.56% for the febuxostat group from day 8 through 28 (P = 0.492). CONCLUSION: Initiation of febuxostat administration during an acute gout flare did not prolong the duration of acute flares. TRIAL REGISTRATION: Chinese Clinical Trial Registry, http://www.chictr.org.cn/, ChiCTR1800015962.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Jia E, Zhang Y, Ma W, et al. Initiation of febuxostat for acute gout flare does not prolong the current episode: a randomized clinical trial. Rheumatology (Oxford). 2021. PMID: 33404656. doi:10.1093/rheumatology/keaa908

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。